{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012457","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.733346+00:00","generated_at":"2026-06-17T01:37:46.432519+00:00","sec_items":["7.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Provectus adds social media channels for investor updates; discontinues email newsletter","bullets":["Will use Substack, Twitter, and LinkedIn for material disclosures.","Discontinuing its emailed newsletter 'Provectus News'.","Investors encouraged to monitor social media in addition to press releases and SEC filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012457","json":"https://secwatch.observer/filing/0001493152-23-012457.json","markdown":"https://secwatch.observer/filing/0001493152-23-012457.md","text":"https://secwatch.observer/filing/0001493152-23-012457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315223012457/0001493152-23-012457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315223012457/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:37:46.432519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}